Baseline risk factors associated with immune related adverse events and atezolizumab

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer patients in the last decade, but immune-related adverse events (irAEs) pose significant clinical challenges. Despite advances in the management of these unique toxicities, there remains an unmet need to furth...

Descripción completa

Detalles Bibliográficos
Autores principales: Madjar, Katrin, Mohindra, Rajat, Durán-Pacheco, Gonzalo, Rasul, Rashad, Essioux, Laurent, Maiya, Vidya, Chandler, G. Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011463/
https://www.ncbi.nlm.nih.gov/pubmed/36925916
http://dx.doi.org/10.3389/fonc.2023.1138305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011463/
https://www.ncbi.nlm.nih.gov/pubmed/36925916
http://dx.doi.org/10.3389/fonc.2023.1138305

Ejemplares similares